Nanoscrips

NanoScrips is developing novel, patent pending prodrugs and nanoparticles which significantly enhance the safety and efficacy of respective drugs. This is achieved by covalent binding of active ingredient to polymers via ester links. The drugs are released in the body by the action of esterases over an extended period of time. The current pipeline of candidates are for glaucoma, retinal neurodegeneration, radiation sensitization of tumor (ex: Glioblastoma/Brain cancer), NASH/Liver fibrosis, Ulcerative colitis, Epilepsy and Alzheimer's. The company has one NIH funded grant for testing its efficacy in retinal disorder. NanoScrips has research agreements with the universities and National Institutes.